Cargando…

RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design

BACKGROUND: Dramatic improvements in spinal muscular atrophy (SMA) treatment have changed the prognosis for patients with this disease, leading to important new questions. Gathering representative, real-world data about the long-term efficacy and safety of emerging SMA interventions is essential to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finkel, Richard S., Day, John W., De Vivo, Darryl C., Kirschner, Janbernd, Mercuri, Eugenio, Muntoni, Francesco, Shieh, Perry B., Tizzano, Eduardo, Desguerre, Isabelle, Quijano-Roy, Susana, Saito, Kayoko, Droege, Marcus, Dabbous, Omar, Khan, Farid, Renault, Lydie, Anderson, Frederick A., Servais, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739962/ https://www.ncbi.nlm.nih.gov/pubmed/32039859 http://dx.doi.org/10.3233/JND-190451

Ejemplares similares

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
por: Kirschner, Janbernd, et al.
Publicado: (2020)

Scientific rationale for a higher dose of nusinersen
por: Finkel, Richard S., et al.
Publicado: (2022)

Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model
por: MacCannell, Drew, et al.
Publicado: (2022)

Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2023)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study
por: Polinski, Jennifer M, et al.
Publicado: (2012)

Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST
por: Cowie, Martin R., et al.
Publicado: (2020)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Transaortic transcatheter aortic valve implantation - rationale and design of the multicenter, multinational prospective ROUTE registry
por: Bramlage, Peter, et al.
Publicado: (2014)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Multinational, observational study of procalcitonin in ICU patients with presumed or confirmed pneumonia and requiring mechanical ventilation
por: Brunkhorst, F, et al.
Publicado: (2006)

International surveillance study in acute spinal cord injury confirms viability of multinational clinical trials
por: Bourguignon, Lucie, et al.
Publicado: (2022)

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
por: Schorling, David C., et al.
Publicado: (2020)

DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results
por: Finkel, Richard S., et al.
Publicado: (2023)

Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
por: Kiefer, Petra, et al.
Publicado: (2020)

Multinational democracies /
Publicado: (2001)

Multinational corporations
Publicado: (1990)

The multinational corporation
por: Liebenau, Jonathan
Publicado: (1984)

Multinational Telecommunications
por: Collective
Publicado: (1977)

Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives
por: DE LOS ANGELES BEYTÍA, MARIA, et al.
Publicado: (2012)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Multinational business finance /
por: Eiteman, David K.
Publicado: (2001)

Multinational business finance /
por: Eiteman, David K.
Publicado: (1998)

Multinational business finance /
por: Eiteman, David K.
Publicado: (1992)

The New Mission for Multinationals
por: Santos, José
Publicado: (2015)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study
por: Ray, Kausik K., et al.
Publicado: (2021)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

Multinational enterprises and the global economy /
por: Dunning, John H.
Publicado: (1993)

International business and multinational enterprises
por: Robock, Stefan Hyman, 1915-
Publicado: (1989)

Multinational Corporation Subsidiaries in China
por: Zhao, Jinghua
Publicado: (2012)

Multinational enterprises and social policy
por: International Labour Office, Geneva
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_jsuu935d248pmdc3mhteaknqj7